Is Seladelpar suitable for treating patients with cirrhosis?

Seladelpar(Seladelpar) is an oral PPARδ receptor agonist, mainly used for adultsprimary biliary cholangitis(PBC), especially for patients who have poor response to or cannot tolerate ursodeoxycholic acid (UDCA). The medication is taken as a once-daily oral capsule to facilitate long-term disease management. However, use in patients with cirrhosis should be done with extreme caution. According to the drug instructions and clinical studies, Siladepa is not suitable for patients with advanced liver disease, that is, patients with decompensated cirrhosis, such as ascites, esophageal and gastric variceal bleeding, or hepatic encephalopathy. Such patients have severely impaired liver function and reduced drug metabolism, which can easily lead to accumulation of drugs in the body and potential toxicity, and the efficacy is also uncertain.

In patients with early or moderate hepatic fibrosis, Siladepa can have a positive effect on liver function indicators by improving cholestasis, reducing inflammatory response and slowing down the progression of fibrosis. For patients who cannot tolerate UDCA, Siladepa can be used as a single drug treatment; for patients with poor response to UDCA, Siladepa can be used in combination to improve biochemical indicators and disease activity. However, for patients with advanced decompensated cirrhosis, the use of seladapa, either as a single agent or in combination, is not recommended. Doctors will combineChild-Pugh classification, liver function test results and complications to assess individualized risks and choose alternative treatments or close monitoring.

It should be emphasized that the liver metabolic capacity and potential risk of complications must be considered when using any drug in patients with cirrhosis. SiladepaIn patients with early to intermediate stagePBC can effectively control the disease, improve liver function, and delay the occurrence of cholestasis-related complications, but it should be used with caution or avoided in patients with advanced stages. During use, patients need to regularly review liver function, bilirubin levels and blood routine, and follow the doctor's medication guidance to ensure efficacy and safety.

Reference materials:https://go.drugbank.com/drugs/DB12390